Baseline demographic and clinical characteristics according to treatment group
| . | HU (n = 38) . | IFNα-2a (n = 82) . | IFNα-2b (n = 82) . | Total (n = 202) . |
|---|---|---|---|---|
| Patient-related variable | ||||
| MPN subtype | ||||
| ET | 9 (24) | 30 (37) | 33 (40) | 72 (36) |
| PV | 21 (55) | 34 (41) | 34 (41) | 89 (44) |
| Pre-MF | 1 (3) | 9 (11) | 6 (7) | 16 (8) |
| PMF | 7 (18) | 9 (11) | 9 (11) | 25 (12) |
| Age, median (range), y | 68 (60-80) | 60 (21-88) | 58 (20-81) | 62 (20-88) |
| Age group | ||||
| ≤60 y | 0 (0) | 45 (55) | 45 (55) | 90 (45) |
| >60 y | 38 (100) | 37 (45) | 37 (45) | 112 (55) |
| Biological sex | ||||
| Female | 14 (37) | 37 (45) | 39 (48) | 90 (45) |
| Male | 24 (63) | 45 (55) | 43 (52) | 112 (55) |
| History of major thrombosis | 6 (16) | 21 (25) | 12 (15) | 39 (19) |
| History of prior stroke | 3 (8) | 10 (12) | 4 (5) | 17 (8) |
| Phenotypic driver mutation | ||||
| JAK2* | 31 (84) | 62 (80) | 57 (80) | 150 (74) |
| CALR | 6 (16) | 10 (14) | 13 (17) | 29 (14) |
| MPL† | 1 (3) | 4 (6) | 5 (6) | 10 (5) |
| Triple-negative | 1 (3) | 4 (5) | 11 (12) | 16 (8) |
| Disease-related variable | ||||
| Hemoglobin, mmol/L | 9.3 (7.9-10.2) | 9.0 (8.3-9.9) | 8.9 (8.1-9.5) | 9.0 (8.2-9.8) |
| Hematocrit, vol % | 45 (41-52) | 45 (42-47) | 43 (40-47) | 44 (41-49) |
| WBC, ×109/L | 9.9 (8.1-11.5) | 8.9 (7.6-11.6) | 9.5 (7.8-12.7) | 9.4 (7.7-11.7) |
| Platelets, ×109/L | 664 (552-895) | 712 (480-930) | 615 (484-852) | 667 (502-904) |
| Lactate dehydrogenase, U/L | 242 (216-288) | 232 (180-296) | 224 (177-294) | 229 (184-294) |
| Splenomegaly on imaging, ≥13 cm | 15/30 (50) | 21/50 (42) | 31/60 (52) | 67/140 (48) |
| Disease-related symptoms‡ | 19 (50) | 51 (62) | 40 (49) | 110 (54) |
| Pretreatment | ||||
| HU | 4 (11) | 10 (12) | 7 (9) | 21 (10) |
| Phlebotomy | 17 (45) | 34 (41) | 39 (48) | 90 (45) |
| . | HU (n = 38) . | IFNα-2a (n = 82) . | IFNα-2b (n = 82) . | Total (n = 202) . |
|---|---|---|---|---|
| Patient-related variable | ||||
| MPN subtype | ||||
| ET | 9 (24) | 30 (37) | 33 (40) | 72 (36) |
| PV | 21 (55) | 34 (41) | 34 (41) | 89 (44) |
| Pre-MF | 1 (3) | 9 (11) | 6 (7) | 16 (8) |
| PMF | 7 (18) | 9 (11) | 9 (11) | 25 (12) |
| Age, median (range), y | 68 (60-80) | 60 (21-88) | 58 (20-81) | 62 (20-88) |
| Age group | ||||
| ≤60 y | 0 (0) | 45 (55) | 45 (55) | 90 (45) |
| >60 y | 38 (100) | 37 (45) | 37 (45) | 112 (55) |
| Biological sex | ||||
| Female | 14 (37) | 37 (45) | 39 (48) | 90 (45) |
| Male | 24 (63) | 45 (55) | 43 (52) | 112 (55) |
| History of major thrombosis | 6 (16) | 21 (25) | 12 (15) | 39 (19) |
| History of prior stroke | 3 (8) | 10 (12) | 4 (5) | 17 (8) |
| Phenotypic driver mutation | ||||
| JAK2* | 31 (84) | 62 (80) | 57 (80) | 150 (74) |
| CALR | 6 (16) | 10 (14) | 13 (17) | 29 (14) |
| MPL† | 1 (3) | 4 (6) | 5 (6) | 10 (5) |
| Triple-negative | 1 (3) | 4 (5) | 11 (12) | 16 (8) |
| Disease-related variable | ||||
| Hemoglobin, mmol/L | 9.3 (7.9-10.2) | 9.0 (8.3-9.9) | 8.9 (8.1-9.5) | 9.0 (8.2-9.8) |
| Hematocrit, vol % | 45 (41-52) | 45 (42-47) | 43 (40-47) | 44 (41-49) |
| WBC, ×109/L | 9.9 (8.1-11.5) | 8.9 (7.6-11.6) | 9.5 (7.8-12.7) | 9.4 (7.7-11.7) |
| Platelets, ×109/L | 664 (552-895) | 712 (480-930) | 615 (484-852) | 667 (502-904) |
| Lactate dehydrogenase, U/L | 242 (216-288) | 232 (180-296) | 224 (177-294) | 229 (184-294) |
| Splenomegaly on imaging, ≥13 cm | 15/30 (50) | 21/50 (42) | 31/60 (52) | 67/140 (48) |
| Disease-related symptoms‡ | 19 (50) | 51 (62) | 40 (49) | 110 (54) |
| Pretreatment | ||||
| HU | 4 (11) | 10 (12) | 7 (9) | 21 (10) |
| Phlebotomy | 17 (45) | 34 (41) | 39 (48) | 90 (45) |